PMC:7600245 / 23590-24063 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T87","span":{"begin":96,"end":104},"obj":"Disease"},{"id":"T88","span":{"begin":105,"end":114},"obj":"Disease"},{"id":"T89","span":{"begin":415,"end":430},"obj":"Disease"},{"id":"T90","span":{"begin":421,"end":430},"obj":"Disease"}],"attributes":[{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A88","pred":"mondo_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A89","pred":"mondo_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A90","pred":"mondo_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Furthermore, an open-label, prospective, randomized, multicenter study in adults (n = 236) with COVID-19 pneumonia in China revealed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for 7–10 days) was associated with a higher 7-day clinical recovery rate compared to a control group treated with umifenovir, a potential inhibitor of the membrane fusion stage during the virus infection, (200 mg three times daily for 7–10 days)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T221","span":{"begin":21,"end":26},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T222","span":{"begin":262,"end":263},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T223","span":{"begin":312,"end":313},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T224","span":{"begin":353,"end":354},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T225","span":{"begin":382,"end":390},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T226","span":{"begin":415,"end":420},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Furthermore, an open-label, prospective, randomized, multicenter study in adults (n = 236) with COVID-19 pneumonia in China revealed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for 7–10 days) was associated with a higher 7-day clinical recovery rate compared to a control group treated with umifenovir, a potential inhibitor of the membrane fusion stage during the virus infection, (200 mg three times daily for 7–10 days)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T325","span":{"begin":21,"end":26},"obj":"Chemical"},{"id":"T326","span":{"begin":138,"end":149},"obj":"Chemical"},{"id":"T327","span":{"begin":322,"end":327},"obj":"Chemical"},{"id":"T328","span":{"begin":341,"end":351},"obj":"Chemical"},{"id":"T329","span":{"begin":365,"end":374},"obj":"Chemical"}],"attributes":[{"id":"A325","pred":"chebi_id","subj":"T325","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A326","pred":"chebi_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A327","pred":"chebi_id","subj":"T327","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A328","pred":"chebi_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A329","pred":"chebi_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Furthermore, an open-label, prospective, randomized, multicenter study in adults (n = 236) with COVID-19 pneumonia in China revealed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for 7–10 days) was associated with a higher 7-day clinical recovery rate compared to a control group treated with umifenovir, a potential inhibitor of the membrane fusion stage during the virus infection, (200 mg three times daily for 7–10 days)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T44","span":{"begin":382,"end":397},"obj":"http://purl.obolibrary.org/obo/GO_0061025"}],"text":"Furthermore, an open-label, prospective, randomized, multicenter study in adults (n = 236) with COVID-19 pneumonia in China revealed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for 7–10 days) was associated with a higher 7-day clinical recovery rate compared to a control group treated with umifenovir, a potential inhibitor of the membrane fusion stage during the virus infection, (200 mg three times daily for 7–10 days)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T12","span":{"begin":105,"end":114},"obj":"Phenotype"}],"attributes":[{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Furthermore, an open-label, prospective, randomized, multicenter study in adults (n = 236) with COVID-19 pneumonia in China revealed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for 7–10 days) was associated with a higher 7-day clinical recovery rate compared to a control group treated with umifenovir, a potential inhibitor of the membrane fusion stage during the virus infection, (200 mg three times daily for 7–10 days)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T173","span":{"begin":0,"end":473},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Furthermore, an open-label, prospective, randomized, multicenter study in adults (n = 236) with COVID-19 pneumonia in China revealed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for 7–10 days) was associated with a higher 7-day clinical recovery rate compared to a control group treated with umifenovir, a potential inhibitor of the membrane fusion stage during the virus infection, (200 mg three times daily for 7–10 days)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"653","span":{"begin":138,"end":149},"obj":"Chemical"},{"id":"654","span":{"begin":341,"end":351},"obj":"Chemical"},{"id":"663","span":{"begin":96,"end":114},"obj":"Disease"},{"id":"664","span":{"begin":415,"end":430},"obj":"Disease"}],"attributes":[{"id":"A653","pred":"tao:has_database_id","subj":"653","obj":"MESH:C462182"},{"id":"A654","pred":"tao:has_database_id","subj":"654","obj":"MESH:C086979"},{"id":"A663","pred":"tao:has_database_id","subj":"663","obj":"MESH:C000657245"},{"id":"A664","pred":"tao:has_database_id","subj":"664","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Furthermore, an open-label, prospective, randomized, multicenter study in adults (n = 236) with COVID-19 pneumonia in China revealed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for 7–10 days) was associated with a higher 7-day clinical recovery rate compared to a control group treated with umifenovir, a potential inhibitor of the membrane fusion stage during the virus infection, (200 mg three times daily for 7–10 days)."}